We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CGEM market cap is 699.9M. The company's latest EPS is USD -2.6304 and P/E is -4.57.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -44.8M | -45.93M | -42.99M | -50.03M | -48.86M |
| Net Income | -39.18M | -23.8M | -37.15M | -42.03M | -40.56M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 18.94M | 0 | 0 |
| Operating Income | -22.27M | -60.34M | -67.95M | -132.14M | -191.09M |
| Net Income | -20.66M | -51.8M | -65.57M | 111.21M | -153.16M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 494.71M | 484.18M | 449.43M | 681.22M | 653.25M |
| Total Liabilities | 25.89M | 30.29M | 23.77M | 25M | 25.39M |
| Total Equity | 468.82M | 453.9M | 425.67M | 656.22M | 627.86M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 100.46M | 214.71M | 437.19M | 561.12M | 484.18M |
| Total Liabilities | 2.6M | 14.39M | 11.81M | 26.09M | 30.29M |
| Total Equity | -39.91M | -76.34M | 425.37M | 535.03M | 453.9M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -116.14M | -134.33M | -38.25M | -74.54M | -108.68M |
| Investing | -15.66M | 35.81M | 12.96M | -172.16M | -152.28M |
| Financing | 40.5M | 40.75M | 1.09M | 263.28M | 264.61M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -20.9M | -29.77M | -43.43M | -126.66M | -134.33M |
| Investing | -35.4M | -5.42M | -333.78M | 248.98M | 35.81M |
| Financing | 85.72M | 140.14M | 268.78M | -25.93M | 40.75M |
| Market Cap | 699.9M |
| Price to Earnings Ratio | -4.57 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 7.12 |
| Price to Book Ratio | 1.54 |
| Dividend Yield | - |
| Shares Outstanding | 58.23M |
| Average Volume (1 week) | 605.5k |
| Average Volume (1 Month) | 523.86k |
| 52 Week Change | 24.17% |
| 52 Week High | 30.1886 |
| 52 Week Low | 9.55 |
| Spread (Intraday) | 6 (34.29%) |
| Company Name | Cullinan Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.cullinantherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
